Ajanta Pharma Limited, announced US FDA approval and launch of amlodipine + olmesartan medoxomil tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Azor tablets and company has launched the product in 4 strengths, 5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg tablets.
Amlodipine + olmesartan medoxomil tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Application (ANDA) of which it has for 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with US FDA.